MedTrace Logo

Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention

NCT02273700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2016-08-24

No results posted yet for this study

Summary

The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better understand the mechanisms of action of these molecules and perform exploratory analyses concerning proteins whose concentrations change after starting treatment.

Conditions

Interventions

DRUG

Rivaroxaban

Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Géraldine Lavigne-Lissalde, MD · Centre Hospitalier Universitaire de Nîmes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273700 on ClinicalTrials.gov